A molecular dynamics investigation into the mechanisms of alectinib resistance of three ALK mutants

Molecular Dynamics Validation of Crizotinib Resistance to ALK Mutations (L1196M and G1269A) and Identification of Specific Inhibitors

(2017) Nagarajan Nagasundaram et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

(2017) David S. Ettinger et al.   Journal of the National Comprehensive Cancer Network

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F

(2016) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Assessing the performance of the MM/PBSA and MM/GBSA methods. 6. Capability to predict protein–protein binding free energies and re-rank binding poses generated by protein–protein docking

(2016) Fu Chen et al.   PHYSICAL CHEMISTRY CHEMICAL PHYSICS

Insight on Mutation-Induced Resistance from Molecular Dynamics Simulations of the Native and Mutated CSF-1R and KIT

(2016) Priscila Da Silva Figueiredo Celestino Gomes et al.   PLoS One

Biological activities of imidazo[2,1-b][1,3,4]thiadiazole derivatives: A review

(2016) Bhoomendra A. Bhongade et al.   Journal of Saudi Chemical Society

ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB

(2015) James A. Maier et al.   Journal of Chemical Theory and Computation

Computationally unraveling how ceritinib overcomes drug-resistance mutations in ALK-rearranged lung cancer

(2015) Zhong Ni et al.   JOURNAL OF MOLECULAR MODELING

I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib

(2015) Sai-Hong Ignatius Ou et al.   LUNG CANCER

Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer

(2014) Namrata Vijayvergia et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance

(2014) Tatsushi Kodama et al.   CANCER LETTERS

Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib

(2014) R. Katayama et al.   CLINICAL CANCER RESEARCH

Updated Data of a Phase 1/2 Study (AF-001JP) of Alectinib, a CNS-Penetrant, Highly Selective ALK Inhibitor in ALK-rearranged Advanced NSCLC

(2014) T. Tamura et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Overcoming Drug Resistance in ALK-Rearranged Lung Cancer

(2014) Roman K. Thomas   NEW ENGLAND JOURNAL OF MEDICINE

Assessing the performance of MM/PBSA and MM/GBSA methods. 5. Improved docking performance using high solute dielectric constant MM/GBSA and MM/PBSA rescoring

(2014) Huiyong Sun et al.   PHYSICAL CHEMISTRY CHEMICAL PHYSICS

Prospects on Strategies for Therapeutically Targeting Oncogenic Regulatory Factors by Small-Molecule Agents

(2013) Chih-Chien Chou et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study

(2013) Takashi Seto et al.   LANCET ONCOLOGY

A Pareto-Optimal Refinement Method for Protein Design Scaffolds

(2013) Lucas Gregorio Nivón et al.   PLoS One

High-Resolution Comparative Modeling with RosettaCM

(2013) Yifan Song et al.   STRUCTURE

Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer

(2012) Robert C. Doebele et al.   CLINICAL CANCER RESEARCH

ALK Gene Amplified in Most Inflammatory Breast Cancers

(2012) R. S. Tuma   JNCI-Journal of the National Cancer Institute

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

(2012) D Ross Camidge et al.   LANCET ONCOLOGY

Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802)

(2011) Kazutomo Kinoshita et al.   BIOORGANIC & MEDICINAL CHEMISTRY

CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant

(2011) Hiroshi Sakamoto et al.   CANCER CELL

Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors

(2011) C. M. Lovly et al.   CANCER RESEARCH

Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)

(2011) J. Jean Cui et al.   JOURNAL OF MEDICINAL CHEMISTRY

9-Substituted 6,6-Dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as Highly Selective and Potent Anaplastic Lymphoma Kinase Inhibitors

(2011) Kazutomo Kinoshita et al.   JOURNAL OF MEDICINAL CHEMISTRY

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK

(2011) R. Katayama et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain

(2010) Christian C. Lee et al.   BIOCHEMICAL JOURNAL

Cell Signaling by Receptor Tyrosine Kinases

(2010) Mark A. Lemmon et al.   CELL

Drug–target residence time: critical information for lead optimization

(2010) Hao Lu et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Residence Time of Receptor−Ligand Complexes and Its Effect on Biological Function

(2008) Peter J. Tummino et al.   BIOCHEMISTRY

Identification of ALK as a major familial neuroblastoma predisposition gene

(2008) Yaël P. Mossé et al.   NATURE

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

(2008) Isabelle Janoueix-Lerosey et al.   NATURE